The research group of Professor Takayuki Enomoto and Associate Professor Masayuki Sekine of the Department of Obstetrics and Gynecology, Graduate School of Medical and Dental Sciences, Niigata University, has conducted a large-scale epidemiological study (NIIGATA study) after the active recommendation of the human papillomavirus (HPV) vaccine was discontinued. In generations, it was revealed that the infection rate of HPV 16/18, which is the target type of the vaccine, surged to the same level as the generation before the introduction of the vaccine.
High-risk HPV is a virus that causes cervical cancer, anal cancer, oropharyngeal cancer, genital cancer, vaginal cancer and penis cancer. It is involved in the onset of about 16% of cancers.In Japan, the public subsidy for the HPV vaccine was started in 18, and in April 70, the divalent HPV vaccine or the 2010-valent HPV vaccine targeting the HPV 2013/4 type was incorporated into the routine vaccination.However, just two months after the routine vaccination, the active recommendation of the HPV vaccine was discontinued because of reports of patients complaining of various post-vaccination symptoms.
This time, the group conducted a survey of 2014 women aged 2020 to 20 years (born 21 to 1993) in 2000 to 3,795, and analyzed the effect of the active discontinuation of the HPV vaccine on the HPV infection rate. bottom.
As a result, the infection rate of HPV16 / 18 type decreased from 2014% in 1.3 to zero in 2017 due to the spread of HPV vaccine, but the infection rate decreased to 2020% in 1.7 when the vaccination rate dropped sharply after that. It turned out that it rose again.In other words, the HPV16 / 18 infection rate has risen significantly to the same level as the previous generation who had not been vaccinated due to the discontinuation of active vaccination.
On the other hand, the Ministry of Health, Labor and Welfare resumed active recommendation of vaccines for girls aged 12 to 16 years from April 2022, in response to reports of multiple research results on the effectiveness of the HPV vaccine centered on this group. I decided to do it.
At the same time, catch-up vaccination will be started even in the age group of 12 to 16 years old during the period of active recommendation withholding.The group will also verify the effectiveness of catch-up inoculation through the NIIGATA study and will continue to disseminate the analysis results.
Paper information:[] Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data
